Integrins and angiogenesis: Unlocking the route to gene therapy

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 6, 2003, Pages 603-610

  Mistry, Ajay ^a   Harbottle, Richard ^c   Steve, Hart ^b   Hodivala Dilke, Kairbaan M ^d  

^a ITX Corporation   (United Kingdom)

^b Molecular Immunology Unit   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Angiogenesis; Gene therapy; Integrins; Targeted vectors

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; CELL ADHESION MOLECULE; DOXORUBICIN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 4; INTEGRIN; INTEGRIN RECEPTOR; MONOCLONAL ANTIBODY LM 609; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CELL INTERACTION; CELL MEMBRANE; CLINICAL TRIAL; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE NUMBER; GENE TARGETING; GENE THERAPY; GENETIC CODE; HEMANGIOMA; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN FAMILY; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ENDOTHELIUM, VASCULAR; GENE THERAPY; GENETIC VECTORS; HUMANS; INTEGRINS; NEOVASCULARIZATION, PATHOLOGIC;

ADENOVIRIDAE;

EID: 0346458894     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86(3):353-364.
2. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature (2000) 407(6801):249-257.
3. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 2(10):727-739.
4. Risau W: Mechanisms of angiogenesis. Nature (1997) 386(6626):671-674.
5. Yancopoulos G, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth factors and blood vessel formation. Nature (2000) 407(6801):242-248.
6. van der Flier A, Sonnenberg A: Function and interactions of integrins. Cell Tissue Res (2001) 305(3):285-298.
7. Hynes RO: Integrins: Versatility modulation and signaling in cell adhesion. Cell (1992) 69(1):11-25.
8. Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell (2002) 110(6):673-687.
9. Albelda SM, Daise M, Levine EM, Buck CA: Identification and characterization of cell-substratum adhesion receptors on cultured human-endothelial cells. J Clin Invest (1989) 83(6):1992-2002.
10. Enenstein J, Kramer RH: Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol (1994) 103(3):381-386.
11. Max R, Gerritsen RC, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ, De Waal RM: Immunohistochemical analysis of integrin αvβ3 expression on tumor associated vessels of human carcinomas - Implications for anti-anglogenic treatment approaches. EurJ Cancer (1997) 33(Suppl 8):S48-S49.
12. Stephens LE, Sutherland AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA, Damsky CH: Deletion of β1 integrins in mice results in inner cell mass failure and ped-implantation lethality. Genes Dev (1995) 9(15):1883-1895.
13. Fassler R, Pfaff M, Murphy J, Noegel AA, Johansson S, Timpl R, Albrecht R: Lack of β1 integrin gene in embyronic stem cells affects morphology, adhesion, and migration but not integration into the inner cell mass of blastocysts. J Cell Biol (1995) 128(5):979-988.
14. Bloch W, Forsberg E, Lentini S, Brakebusch C, Martin K, Krell HW, Weidle UH, Addicks K, Fassler R: β1 Integrin is essential for teratoma growth and angiogenesis. J Cell Biol (1997) 139(l):265-278.
15. Yang JT, Rayburn H, Hynes RO: Embryonic mesodermal defects in α5 integrin-deficient mice. Development (1993) 119(4):1093-1105.
16. Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D, Hynes RO: Central roles of α501 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol (2002) 22(6):927-933.
17. Taverna D, Hynes RO: Reduced blood vessel formation and tumor growth in α5-Integrin-negative teratocarcinomas and embryoid bodies. Cancer Res (2001) 61(13):5255-5261.
18. Kim S, Bell K, Mousa SA, Varner JA: Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol (2000) 156(4 ):1345-1362.
19. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo CR, Pihlajaniemi T, Alitalo K, Vuori K: Interaction of enclostatin with integrins implicated in anglogenesis. Proc Natl Acad Sci USA (2001) 98(3):1024-1029.
20. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M: Angiogenesis promoted by vascular enclothelial growth factor: Regulation through α1β1 and α2β1 integrins. Proc Natl Acad Sci USA (1997) 94(25):13612-13617.
21. Funahashi Y, Sugi NH, Semba T, Yamamoto Y, Hamaoka S, Tsukahara-Tamai N, Ozawa Y, Tsuruoka A, Nara K, Takahashi K, Okabe T et at. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin α2 subunit on enclothellum. Cancer Res (2002) 62(21):6116-6123.
22. Gardner H, Kreidberg J, Koteliansky V, Jaenisch R: Deletion of integrin α1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev Biol (1996) 175(2):301-313.
23. Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM: The α2 integrin subunit-deficient mouse: A multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol (2002) 161(1):337-344.
24. Drake CJ, Cheresh DA, Little CD: An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci (1995) 108(7):2655-2661.
25. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA: Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases. Proc Natl Acad Sci USA (11996) 93(18):9764-9769.
26. Hammes HP, Brownlee M, Jonczyk A, Suffer A, Preissner KT: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med (1996) 2(5):529-533.
27. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA: Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist. J Clin Invest (11999) 103(1 ):47-54.
28. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157-1164.
29. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA: Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest (1995) 96(4 ):1815-1822.
30. Varner KA, Cheresh DA: Integrins and cancer. Curr Opin Cell Biol (1996) 8(15):724-730.
31. Eliceiri BP, Cheresh DA: The role of αv integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest (1999) 103(9):1227-1230.
32. Eliceiri BP, Cheresh DA: Adhesion events in angiogenesis. Curr Opin Cell Biol (2001) 13(5):563-568.
33. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA: Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin αvβ3. Clin Cancer Res (2000) 6(8):3056-3061.
34. Bader BL, Rayburn H, Crowley D, Hynes RO: Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins. Cell (1998) 95(4):507-519.
35. Hodivala-Dilke K, McHugh KP, Tsakins DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO: β3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest (1999) 103(2):229-238.
36. Huang X, Griffiths M, Wu J, Farese RV Jr, Sheppard D: Normal development, wound healing, and adenovirus susceptibility in β5-deficient mice. Mol Cell Biol (2000) 20(3):755-759.
37. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM: Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat Med (2002) 8(l):27-34.
38. Stupack DG, Cheresh DA: ECM remodelling regulates angiogenesis: Endothelial integrins look for new ligands. Sci STKE (2002) 2002 (119):PE7.
39. Hodivala-Dilke KM, Reynolds AR, Reynolds LE: Integrins in angiogenesis: Multitalented molecules in a balancing act. Cell Tissues Res (2003) 314(1):131-144.
40. Arap W, Pasqualini R, Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (1998) 279(5349):377-380.
41. Feigner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M: Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA (1987) 84(21):7413-7417.
42. Hirko A, Tang F, Hughes JA: Cationic lipid vectors for plasmid DNA delivery. Curr Med Chem (2003) 10(14):1185-1193.
43. Isberg RR: Discrimination between intracellular uptake and surface adhesion of bacterial pathogens. Science (1991) 252(2008):934-938.
44. Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkonen K, Wright SD: Recognition of a bacterial adhesion by an integrin: Macrophage CR3 (αMβ2, CD11b CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell (1990) 61(7):1375-1382.
45. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell (1993) 73(2):309-319.
46. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW: Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science (11997) 275(5304):1320-1323.
47. Guerrero CA, Mendez E, Zarate S, Isa P, Lopez S, Arias CF: Integrin αvβ3 mediates rotavirus cell entry. Proc Natl Acad Sci USA (2000) 97(26):14644-14649.
48. Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, Lea S, Lewis R, Newman J, Parry N, Rowlands D et at. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature (1993) 362(6420):566-568.
49. Lehrman S: Virus treatment questioned after gene therapy death. Nature (1999) 401(6753):517-518.
50. Summerford C, Bartlett JS, Samulski RJ: αvβ5 Integrin: A co-receptor for adeno-associated virus type 2 infection. Nat Med (11999) 5(1):78-82.
51. Hart SL, Knight AM, Harbottle RP, Mistry A, Hunger HD, Cutler DF, Williamson R, Coutelle C: Cell-binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem (11994) 269(17):12468-12474.
52. Hart SL, Collins L, Gustafsson K, Fabre JW: Integrin-mediated transfection with peptides containing arginine-glycine-aspartic acid domains. Gene Ther (1997) 4(11):1225-1230.
53. Hart SL, Arancibia-Carcamo CV, Wolfert MA, Mailhos C, O'Reilly NJ, Ali RR, Coutelle C, George AJT, Harbottle RP, Knight AM, Larkin DFP et al: Upid-mediated enhancement of transfection by a nonviral integrin-targeting vector. Hum Gene Ther (1998) 9(4):575-585.
54. Harbottle RP, Cooper RG, Hart SL, Ladhoff A, McKay T, Knight AM, Wagner E, Miller AD, Coutelle C: An RGD-oligolysine peptide: A prototype construct for integrin-mediated gene delivery. Hum Gene Ther (1998) 9(7):1037-1047.
55. Jenkins RG, Meng QH, Hodges RJ, Lee LK, Bottoms SE, Laurent GJ, Willis D, Ayazi Shamlou P, McAnulty RJ, Hart SL: Formation of LID vector complexes in water alters physicochemical properties and enhances pulmonary gene expression in vivo. Gene Ther (2003) 10(12):1026-1034.
56. Siapati KE, Barker S, Kinnon C, Michalski A, Anderson R, Brickell P, Thrasher AJ, Hart SL: Improved antitumor immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer (2003) 88(10):1641-1648.
57. Cunningham S, Meng QH, Klein N, McAnulty RJ, Hart SL: Evaluation of a porcine model for pulmonary gene transfer using a novel synthetic vector. J Gene Med (2002) 4(4):438-446.
58. Yla-Herttuala S, Alitalo K: Gene transfer as a tool to induce therapeutic vascular growth. Nat Med (2003) 9(6):694-701.
59. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A, Vanninen E, Mussalo H, Kauppila E, Simula S, Narvanen O et al: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio angiogenesis trial (KAT). Circulation (2003) 107(21):2677-2683.
60. Mukherjee D, Dey S, Lingam P, Chetcuti SJ, Grossman PM, Moscucci M, Rajagopalan S, Luciano AE, Eagle KA: Predictors of clinical outcome in patients undergoing peripheral vascular interventions: Insights from the University of Michigan peripheral vascular disease quality improvement initiative (PVD-Q12). J Am Coll Cardiol (2003) 41(6 Suppi A):75A.
61. Rebar EJ, Huang Y, Hickey R, Nath AK, Meoli D, Nath S, Chen B, Xu L, Liang Y, Jamieson AC, Zhang L et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 8(12):1427-1432.
62. Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Quertermous T, Coleman M, Boudreau N, Varner JA: Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest (2003) 112(1):30-41.
63. Kuo CJ, Famebo F, Yu EY, Christofferson R, Swearingen RA, Carter R, von Recum HA, Yuan J, Kamihara J, Flynn E, D'Amato R et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA (2001) 98(8):4605-4610.
64. Bainbridge JWB, Mistry A, De Alwis M, Paleolog E, Baker A, Thrasher AJ, Ali RR: Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther (2002) 9(5):320-326.
65. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277-285.
66. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases; by a Lewis lung carcinoma. Cell (1994) 79(2):315-328.
67. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW, Pizzo SV: Angiostatin binds ATP synthase on the surface of human enclothellal cells. Proc, Natl Acad Sci USA (1999) 96(6):2811-2816.
68. Troyanovsky B, Levchenko T, Mansson G, Matvijenko O, Holmgren L: Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol (2001) 152(6):1247-1254.
69. Raisler BJ, Berns KI, Grant MB, Beliaev D, Hauswirth WW: Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA (2002) 99(13):8909-8914.
70. Lai CM, Brankov M, Zaknich T, Lai YK-Y, Shen WY, Constable IJ, Kovesdi I, Rakoczy PE: Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther (2001) 12(10):1299-1310.
71. Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, Penn M, Chen CT, Melia M, Phipps S, Moffat D et at. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol (2001) 159(1):313-320.
72. Bainbridge JWB, Mistry A, Schlichtenbrede FC, Smith A, Broderick C, De Alwis M, Georgiadis A, Taylor PM, Squires M, Sethi C, Charteris D et al. Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina. Gene Ther(2003) 10(16):1336-1344.
73. Reich SJ, Bennett J: Gene therapy for ocular neovascularization: A cure in sight. Curr Opin Genet Dev (2003) 13(3):317-322.
74. Cheresh DA: Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA (1987) 84(18):6471-6475.
75. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA: Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 296(5577):2404-2407.
76. Reynolds AR, Moein Moghimi S, Hodivala-Dilke K: Nanoparticle-mediated gene delivery to tumor neovasculature. Trends Mol Med (2003) 9(1):2-4.
77. Parkes R, Meng QH, Elena Siapati K, McEwan JR, Hart SL: High efficiency transfection of porcine vascular cells in vitro with a synthetic vector system. J Gene Med (2002) 4(3):292-299.
78. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi 1: Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol (1996) 70(10):6831-6838.
79. Wickham TJ, Haskard D, Segal D, Kovesdi I: Targeting endothelium for gene therapy via receptors up-regulated during angiogenesis and inflammation. Cancer Immunnol Immunother (1997) 45(3-4):149-151.
80. D'Amato R, Wesolowski E, Smith LE: Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc Res (1993) 46(2):135-142.
81. Dmitriev IP, Kashentseva EA, Curiel DT: Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 76(14):6893-6899.
82. Grill J, Van Beusechem VW, Van der Valk P, Dirven CM, Leonhart A, Pherai DS, Haisma HJ, Pinedo HM, Curiel DT, Gerritsen WR: Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res (2001) 7(3):641-650.
83. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH: Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther(2001) 4(3):174-181.